Celularity Inc

Celularity Inc completed its business combination with GX Acquisition Corp. II, which traded under ticker GXGX on Nasdaq, and filed a Form 10-Q on August 19, 2021. GX Acquisition Corp. II, sponsored by GX Sponsor II LLC, held its initial public offering in 2020 with a focus on life sciences and biotechnology opportunities. Celularity is a clinical-stage cellular medicine company developing placental-derived allogeneic cell therapies across oncology and infectious disease indications. The August 2021 quarterly filing represents an early post-merger reporting milestone for the combined entity following the close of the de-SPAC transaction. Sign up at SpacDesk for full filing histories, deal analytics, and real-time data on GXGX and hundreds of other SPAC transactions.